Please login to the form below

Not currently logged in


This page shows the latest Symkevi news and features for those working in and with pharma, biotech and healthcare.

Vertex continues upward trajectory with French Orkambi deal

Vertex continues upward trajectory with French Orkambi deal

The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor).

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    of CF patients and now Symkevi (ivacaftor and tezacaftor). This is effective for people who have two copies of the F508del mutation plus those with one of 14 other mutations.

  • The Orkambi row explained The Orkambi row explained

    It refuses to file Symkevi with NICE, stating that it will only submit its data if NICE updates its appraisal process. ... December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... The hope is that both sides can come to a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...